BD-1008 (dihydrobromide)

BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM) . BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor[1][2][3].

Product Specifications

CAS Number

[138356-09-9]

UNSPSC

12352005

Target

Sigma Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/bd-1008-dihydrobromide.html

Purity

98.07

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 12.5 mg/mL (ultrasonic)

Smiles

CN(CCC1=CC=C(Cl)C(Cl)=C1)CCN2CCCC2.Br.Br

Molecular Formula

C15H24Br2Cl2N2

Molecular Weight

463.08

References & Citations

[1]Staelens L, et al. In vivo evaluation of [ (123) I]-3- (4-iodobenzyl) -1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D4 receptor ligand for SPECT studies. Nucl Med Biol. 2005 Apr;32 (3) :293-9. |[2]Garcés-Ramírez L, et al. Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry. 2011 Feb 1;69 (3) :208-17.|[3]Hiranita T, et al. Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats. J Pharmacol Exp Ther. 2013 Oct;347 (1) :20-9.